Can PKC Be a Therapeutic Target for Reducing Toxicity?
Yes, targeting PKC offers potential therapeutic avenues for reducing toxicity. Inhibitors of specific PKC isoforms can be designed to mitigate the toxic effects of drugs or environmental agents. For example, PKC inhibitors have shown promise in reducing the cardiotoxic effects of doxorubicin, a widely used chemotherapeutic agent. These findings underscore the potential of PKC as a therapeutic target in toxicology.
